All Oncology News

This roundup includes exclusive insights from 23 clinicians and key data on the top abstracts coming out of the 2024 ESMO Annual Meeting.

Marc J. Braunstein, MD, PhD, discusses the diagnosis, prevention, and treatment of patients with veno-occlusive disease post-transplant.

Hope Rugo, MD, FASCO, discusses the FDA approval of inavolisib, how it will be incorporated into care, and the patient population evaluated in INAVO120.

Sheldon M. Feldman, MD, discusses disparities, post-treatment care, and technological advancements in breast cancer during Breast Cancer Awareness Month.

Domenica Lorusso, MD, PhD, and Premal Thaker, MD, highlight the upcoming phase 3 ROSELLA trial of relacorilant in platinum-resistant ovarian cancer.

Docetaxel treatment was associated with significantly less taxane-induced peripheral neuropathy vs paclitaxel in Black patients with breast cancer.

An NDA seeking the approval of sacituzumab tirumotecan for EGFR-mutant non–small cell lung cancer is under review by the NMPA’s CDE.

First-line sugemalimab plus chemotherapy has received UK approval for metastatic NSCLC without EGFR-sensitizing mutations or ALK/ROS1/RET alterations.

Results of the TALAPRO-2 trial showed that a novel prostate cancer therapy has a higher overall survival rate compared to the standard of care drug alone.

John Strickler, MD, details the latest data on the novel c-Met–targeted ADC telisotuzumab adizutecan and how the agent could affect the treatment of CRC.

The FDA has granted regenerative medicine advanced therapy to ALLO-316 in CD70-positive advanced or metastatic renal cell carcinoma.

The FDA has extended the PDUFA date for sotorasib plus panitumumab application in KRAS G12C+ metastatic colorectal cancer.

Laura J. Chambers, DO, discusses the roles of niraparib and olaparib in ovarian cancer and the importance of patient communication throughout treatment.

Bradley C. Carthon, MD, PhD, discusses recent data and the evolving treatment landscape in prostate cancer.

A Roswell Park study reveals the evolutionary stability of the naked mole-rat’s genome, and implications for drug development.

The FDA has announced that BioZorb Markers and BioZorb LP Markers should no longer be used.

The FDA has received an NDA seeking the approval of a 3-month formulation of leuprolide mesylate for advanced prostate cancer.

Treatment options after progression on anti–PD-1 and BRAF/MEK inhibitors have been limited but TIL therapy has expanded metastatic melanoma treatment.

For more first-hand insights, head over to our YouTube channel to watch Dr Markman discuss the inner workings of oncology: https://rb.gy/bvumdn.

Sheldon M. Feldman, MD, discusses the importance of personalized medicine in breast cancer during Breast Cancer Awareness Month.

Daniel DeAngelo MD, PhD, discusses the evolution of management strategies and treatment goals across several hematologic malignancies.

The FDA has granted accelerated approval to asciminib for newly diagnosed, Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase.

IDE397 is the first MAT2A inhibitor to show clinical activity and safety in patients with MTAP-deletion urothelial cancer and non–small cell lung cancer.

Uproleselan plus 7+3 chemotherapy failed to improve EFS vs chemotherapy alone in older patients with newly diagnosed AML fit for intensive chemotherapy.

The October 2024 NCCN Clinical Practice Guidelines in Oncology for breast cancer recommend ribociclib plus an AI in adjuvant HR+/HER2– early breast cancer.

Higher breast cancer rates among Caribbean women may be linked to shifting patterns in their reproductive health according to data from a Sylvester Comprehensive Cancer Center study.

BGB-16673 had acceptable tolerability and showcased early antitumor activity in patients with relapsed/refractory Waldenström macroglobulinemia.

The FDA has expanded the approval of methotrexate to include use in pediatric patients with acute lymphoblastic leukemia.

Anita Scheuber, MD, PhD, details the mechanism of action of NDI-101150, early data seen with the agent, and next steps in the HPK1 inhibitor’s investigation.

Douglas W. Sborov, MD, MS, discusses where ide-cel and cilta-cel each fit into the myeloma treatment paradigm.